World Journal of Urology

, Volume 31, Issue 6, pp 1321–1325 | Cite as

Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry

  • Philippe E. Spiess
  • David A. Levy
  • Louis L. Pisters
  • Vladimir Mouraviev
  • J. Stephen Jones
Topic Paper

Abstract

Objectives

In this study, we evaluate the outcomes of salvage cryotherapy for locally recurrent prostate cancer within the COLD (cryo online data) Registry. Furthermore, we assess the results of salvage cryotherapy (with intermediate follow-up) stratified by pre-treatment prostate-specific antigen (PSA) levels to determine which patients may best be suited for treatment.

Methods

The COLD registry was developed as a prospective, centrally collected database among patients undergoing salvage cryoablation for locally recurrent prostate cancer following primary prostate radiotherapy with curative intent. Of the patients undergoing salvage cryotherapy (without neoadjuvant hormonal ablative therapy), complete medical records were available in 156 patients, with their mean follow-up being 3.8 years (0.9–12.7 years). The treatment outcomes of salvage cryotherapy were assessed using the Phoenix definition (nadir PSA + 2 ng/ml) of biochemical failure.

Results

Of our entire study population, the biochemical disease-free survival (bDFS) rates at 1, 2, and 3 years were 89.0, 73.7, and 66.7 %, respectively. Stratification of our patients into two subgroups is based on their pre-treatment total serum PSA values <5 and ≥5 ng/ml, and bDFS rates at 3 years for these two subgroups were 78.3 and 52.9 %, respectively. A Kaplan–Meier analysis of bDFS stratified by these same pre-treatment PSA values revealed that the subset of patients with a PSA ≥ 5 ng/ml had statistically significant poorer bDFS rates (P = 0.01).

Conclusions

Salvage prostate cryotherapy is a potentially curative local salvage therapy. The importance of early referral when patients have a pre-treatment PSA < 5 ng/ml is essential to optimize treatment outcomes.

Keywords

Salvage cryotherapy Prostate cancer Prostate-specific antigen Biochemical failure 

References

  1. 1.
    Allen GW, Howard AR, Jarrard DF, Ritter MA (2007) Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer 110:1405–1416PubMedCrossRefGoogle Scholar
  2. 2.
    Pisters LL, Leibovici D, Blute M, Zincke H, Sebo TJ, Slezak JM, Izawa J, Ward JF, Scott SM, Madsen L, Spiess PE, Leibovici BC (2009) Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 182:517–525PubMedCrossRefGoogle Scholar
  3. 3.
    Spiess PE, Given RW, Jones JS (2011) Achieving the ‘bifecta’ using salvage cryotherapy for locally recurrent prostate cancer: analysis of the cryo on-line data (COLD) registry data. BJU Int (published online 12 Oct 2011Google Scholar
  4. 4.
    Izawa JI, Madsen LT, Scott SM, Tran JP, McGuire EJ, von Eschenbach AC, Pisters LL (2002) Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 20:2664–2671PubMedCrossRefGoogle Scholar
  5. 5.
    Pisters LL, Perrotte P, Scott SM, Greene GF, von Eschenbach AC (1999) Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy. J Clin Oncol 17:2514–2520PubMedGoogle Scholar
  6. 6.
    Spiess PE, Lee AK, Leibovici D, Wang X, Do KA, Pisters LL (2006) Presalvage prostate specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 107:275–280PubMedCrossRefGoogle Scholar
  7. 7.
    Greene GF, Pisters LL, Scott SM, Con Eschenbach AC (1998) Predictive value of prostate specific antigen nadir after salvage cryotherapy. J Urol 160:86–90PubMedCrossRefGoogle Scholar
  8. 8.
    Williams AK, Martinez CH, Lu C, Ng CK, Pautler SE, Chin JL (2011) Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. Eur Urol 60:405–410PubMedCrossRefGoogle Scholar
  9. 9.
    Spiess PE, Katz AE, Chin JL, Bahn D, Cohen JK, Shinohara K, Hernandez M, Bossier J, Kassouf W, Pisters LL (2010) A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer. BJU Int 106:194–198PubMedCrossRefGoogle Scholar
  10. 10.
    Ritch CR, Katz AE (2009) Prostate cryotherapy: current status. Curr Opin Urol 19:177–181PubMedCrossRefGoogle Scholar
  11. 11.
    Kaplan EL, Ep M (1958) Nonparametric estimation from incomplete observations. J Am Statist 53:457–481CrossRefGoogle Scholar
  12. 12.
    Mouraviev V, Spiess PE, Jones JS (2012) Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. Eur Urol 61:1204–1211Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Philippe E. Spiess
    • 1
  • David A. Levy
    • 2
  • Louis L. Pisters
    • 3
  • Vladimir Mouraviev
    • 4
  • J. Stephen Jones
    • 2
  1. 1.Department of Genitourinary OncologyMoffitt Cancer CenterTampaUSA
  2. 2.Department of Regional Urology, Glickman Urological and Kidney Institute Cleveland ClinicClevelandUSA
  3. 3.Department of Urologic OncologyAnderson Cancer CenterHoustonUSA
  4. 4.Department of UrologyUniversity of CincinnatiCincinnatiUSA

Personalised recommendations